Merck's Q1 2018 earnings call highlights strong KEYTRUDA performance, particularly in lung cancer, driving revenue growth.  Management projects continued growth through 2021 and beyond, citing strong pipeline in oncology, vaccines, and animal health.  While the call emphasizes positive momentum, the discussion also hints at challenges in achieving consistent operating leverage in the short term due to ongoing investments in R&D and potential pricing pressure on existing products.
[1]
